Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genes and hypertension.

E A Garcia1, S Newhouse, M J Caulfield

  • 1Clinical Pharmacology and the Barts and The London Genome Centre, William Harvey Research Institute, Barts and The London, London, UK.

Current Pharmaceutical Design
|July 23, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The genomic landscape of familial glioma.

Science advances·2023
Same author

Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in bronchiectasis.

The European respiratory journal·2022
Same author

First genome-wide association study investigating blood pressure and renal traits in domestic cats.

Scientific reports·2022
Same author

A genome-wide association study for extremely high intelligence.

Molecular psychiatry·2018
Same author

New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation.

The pharmacogenomics journal·2017
Same author

Multi-polygenic score approach to trait prediction.

Molecular psychiatry·2017

Genetic research has identified new mechanisms for blood pressure control, including novel genes and anti-hypertensive drugs. Understanding genetic variations influencing hypertension and drug response is key to personalized medicine.

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Significant progress in understanding blood pressure regulation has been achieved through studying rare Mendelian hypertension, candidate genes, and genome-wide screening in humans and animal models.
  • New cardiovascular genes, including WNK kinases and angiotensin converting enzyme 2, have been discovered, alongside the development of the anti-hypertensive agent PST2238.

Purpose of the Study:

  • To review recent advancements in identifying blood pressure control mechanisms and genes.
  • To discuss the role of genetics in essential hypertension and response to anti-hypertensive therapy.
  • To highlight the potential of pharmacogenetics in tailoring hypertension treatment.

Main Methods:

  • Review of studies on rare Mendelian hypertension, candidate gene analysis, comparative mapping, and genome-wide screening.

Related Experiment Videos

  • Analysis of newly discovered blood pressure/cardiovascular genes (WNK kinases, angiotensin converting enzyme 2).
  • Examination of pharmacogenetic studies and microarray data on anti-hypertensive therapy response.

    • Main Results:

    • Over 20 genome-wide screens have identified suggestive linkage regions for blood pressure controlling genes.
    • Initial pharmacogenetic studies suggest a small genetic contribution (3-5%) to individual blood pressure response to therapy.
    • Recent microarray analyses indicate that genetic profiles can explain up to 50% of the variation in therapy response, considering additive effects of multiple loci.

    Conclusions:

    • Continued genome-wide screening holds promise for discovering novel blood pressure genes.
    • Understanding genetic variants is crucial for elucidating molecular mechanisms of blood pressure control and developing personalized anti-hypertensive strategies.
    • Pharmacogenetics offers a pathway to optimize anti-hypertensive treatment based on an individual's genetic makeup.